These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 6388898)
21. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Van de Werf F; Bergmann SR; Fox KA; de Geest H; Hoyng CF; Sobel BE; Collen D Circulation; 1984 Mar; 69(3):605-10. PubMed ID: 6362907 [TBL] [Abstract][Full Text] [Related]
25. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis. Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691 [TBL] [Abstract][Full Text] [Related]
26. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. Magnani B J Am Coll Cardiol; 1989 Jan; 13(1):19-26. PubMed ID: 2491867 [TBL] [Abstract][Full Text] [Related]
27. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. Topol EJ; Morris DC; Smalling RW; Schumacher RR; Taylor CR; Nishikawa A; Liberman HA; Collen D; Tufte ME; Grossbard EB J Am Coll Cardiol; 1987 Jun; 9(6):1205-13. PubMed ID: 2953770 [TBL] [Abstract][Full Text] [Related]
28. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis. Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830 [TBL] [Abstract][Full Text] [Related]
29. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Van de Werf F; Nobuhara M; Collen D Ann Intern Med; 1986 Mar; 104(3):345-8. PubMed ID: 3080936 [TBL] [Abstract][Full Text] [Related]
30. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Collen D; Bounameaux H; De Cock F; Lijnen HR; Verstraete M Circulation; 1986 Mar; 73(3):511-7. PubMed ID: 2419009 [TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Tiefenbrunn AJ; Robinson AK; Kurnik PB; Ludbrook PA; Sobel BE Circulation; 1985 Jan; 71(1):110-6. PubMed ID: 4038368 [TBL] [Abstract][Full Text] [Related]
32. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group. Lancet; 1989 Apr; 1(8643):863-8. PubMed ID: 2564949 [TBL] [Abstract][Full Text] [Related]
33. Clot-selective coronary thrombolysis with pro-urokinase. Loscalzo J; Wharton TP; Kirshenbaum JM; Levine HJ; Flaherty JT; Topol EJ; Ramaswamy K; Kosowsky BD; Salem DN; Ganz P Circulation; 1989 Apr; 79(4):776-82. PubMed ID: 2494004 [TBL] [Abstract][Full Text] [Related]
35. Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction. Kambara H; Kawai C; Kajiwara N; Niitani H; Sasayama S; Kanmatsuse K; Kodama K; Sato H; Nobuyoshi M; Nakashima M Circulation; 1988 Oct; 78(4):899-905. PubMed ID: 3139325 [TBL] [Abstract][Full Text] [Related]
36. Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up. Schmidt WG; Uebis R; von Essen R; Effert S; Erbel R; Meyer J; Rutsch W; Schartl M; Schmutzler H Eur Heart J; 1987 Nov; 8(11):1182-8. PubMed ID: 3121335 [TBL] [Abstract][Full Text] [Related]
37. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Goldhaber SZ; Agnelli G; Levine MN Chest; 1994 Sep; 106(3):718-24. PubMed ID: 8082347 [TBL] [Abstract][Full Text] [Related]
38. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience. de Bono DP J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717 [TBL] [Abstract][Full Text] [Related]